Opinion|Videos|June 24, 2024
Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
The panelists examine the latest findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab (nivo + ipi) as a first-line treatment for advanced renal cell carcinoma, focusing on efficacy, safety, and quality of life outcomes.
Advertisement
Episodes in this series
- Please briefly discuss the recent data from the CheckMate 214 trial evaluating nivo + ipi for 1L treatment of advanced RCC.
- 8-year follow-up and subgroup analyses – please comment on OS, DOR, PFS, TFS, and safety (
Tannir et al., ASCO GU 2024 Abstract 363 )
- 8-year follow-up and subgroup analyses – please comment on OS, DOR, PFS, TFS, and safety (
- What insights do the recent HRQoL data provide? (
Cella et al., Oncologist Jan 2024 )
- Please comment on the role of doublet regimens in the 1L setting for advanced RCC and their recent data updates.
- CheckMate 9ER nivo + cabo
- 55-month follow up (
Bourlon et al., ASCO GU 2024 Abstract 362) - HRQoL (
Bedke et al., ASCO GU 2024 Abstract 384 ) - Partitioned 4-year OS (
Mantia et al., ASCO 2024 Abstract 4507 )
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Dana-Farber’s Xin Gu, PhD, and Nicholas Polizzi, PhD, received NIH New Innovator Awards for high-risk, high-reward research.
The c-Met–directed ADC-based combination was designated for mCRC previously treated with fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy.
Pooled data from 3 randomized trials showed ropeginterferon alfa-2b improved responses vs phlebotomy alone but not vs hydroxyurea in polycythemia vera.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
3
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
4
Etentamig, Iberdomide, and Long-Term PERSEUS Data Headline Key Myeloma Findings From IMS 2026
5